HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.

AbstractINTRODUCTION:
Bcl-2 antanogene-1 (Bag-1) binds the anti-apoptotic mediator Bcl-2, and enhances its activity. Bcl-2 and Bag-1 are associated with chemotherapy resistance in cancer cells. Drugs that target Bcl-2 are currently in clinical development. The purpose of the present study was to examine expression patterns of Bag-1 in a large cohort of breast tumors and to assess the association with Bcl-2, estrogen receptor, progesterone receptor and Her2/neu, and other clinical/pathological variables.
METHODS:
Tissue microarrays containing primary specimens from 638 patients with 10-year follow-up were employed, and the expression of Bag-1, Bcl-2, estrogen receptor, progesterone receptor and Her2/neu was assessed using our automated quantitative analysis method. We used cytokeratin to define pixels as breast cancer (tumor mask) within the array spot, and we measured biomarker expression within the mask using Cy5 conjugated antibodies.
RESULTS:
High Bcl-2 expression was associated with improved survival in the entire cohort and in the node-positive subset (P = 0.008 and P = 0.002, respectively). High Bag-1 expression was associated with improved survival in the node-positive subset (P = 0.006). On multivariable analysis, neither Bcl-2 nor Bag-1 retained their independence as prognostic markers. Strong associations were found between Bag-1, Bcl-2, estrogen receptor and progesterone receptor.
CONCLUSION:
Bag-1 and Bcl-2 expression in breast tumors is associated with improved outcome and steroid receptor positivity. Evaluation of Bcl-2 and Bag-1 expression in breast cancer may identify a subset of patients with a favorable prognosis, who might not benefit from chemotherapy or who might benefit from Bcl-2 targeting agents in addition to antihormonal therapy.
AuthorsYasmine Nadler, Robert L Camp, Jennifer M Giltnane, Christopher Moeder, David L Rimm, Harriet M Kluger, Yuval Kluger
JournalBreast cancer research : BCR (Breast Cancer Res) Vol. 10 Issue 2 Pg. R35 ( 2008) ISSN: 1465-542X [Electronic] England
PMID18430249 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • BCL2-associated athanogene 1 protein
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Transcription Factors
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Breast Neoplasms (chemistry, drug therapy, pathology)
  • DNA-Binding Proteins (analysis)
  • Drug Resistance, Neoplasm
  • Female
  • Fluorescent Antibody Technique
  • Follow-Up Studies
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Lymphatic Metastasis
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Protein Array Analysis
  • Proto-Oncogene Proteins c-bcl-2 (analysis)
  • Receptors, Estrogen (analysis)
  • Receptors, Progesterone (analysis)
  • Transcription Factors (analysis)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: